All In Biotech

Drug Trial Radar · NCT07226791

Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants Undergoing Open Abdominal Ventral Hernia Repair

A Phase 2 Double-Blind, Placebo-Controlled, Adaptive, Dose-Escalation Study to Evaluate the Safety and Efficacy of AGN-151607-DP (USAN: gemibotulinumtoxinA) for the Achievement of Primary Fascial Closure Without the Use of Component Separation Technique, in Subjects Undergoing Open Abdominal Ventral Hernia Repair

Last checked: Nov 20, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Feb 4, 2026

Primary completion

Sep 2028

Study completion May 2030

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Nov 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A ventral hernia happens when the muscles in the front of your belly become weak and let organs push through, causing a bulge. If it gets worse, intestines can slip into the bulge, leading to serious pain and health problems. This study aims to asses if AGN-151607-DP is safe and effective for closing the belly wall after open ventral hernia surgery, without needing a complex procedure. Adverse Events and change in disease activity will be assessed. AGN-151607-DP is an investigational drug being developed to treat ventral hernia. Participants will be randomly placed in treatment groups to receive either AGN151607-DP or matching placebo. Approximately 200 adult participants with midline ventral hernia needing open surgical repair will be enrolled in approximately 30 sites in the United States. Participants will receive intramuscular injections of AGN-161607-DP or matching placebo on Day 1. Duration of the study is approximately 25 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular weekly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

  • Ventral Hernia

Interventions

  • AGN-151607-DPDrug

    Intramuscular Injection

  • Placebo for AGN-151607-DPDrug

    Intramuscular Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Primary Fascial Closure (PFC) Without Use of Component Separation Technique (CST) in Open Ventral Hernia Surgical RepairTime frame: Up to approximately 1 Month
  2. Percentage of Participants Experiencing Adverse EventsTime frame: Up to approximately 25 Months

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • CARI Clinical Trials INC /ID# 278844

    Riverside, California · Recruiting

  • University of Florida - Jacksonville /ID# 261992

    Jacksonville, Florida · Completed

  • Medical Research Center /ID# 278680

    Miami, Florida · Recruiting

  • Avanza Medical Research Center /ID# 278885

    Pensacola, Florida · Recruiting

  • NorthShore University-Endeavor Health Evanston Hospital /ID# 277995

    Evanston, Illinois · Recruiting

  • Integrity Clinical Research /ID# 278710

    Wichita, Kansas · Completed

  • Mayo Clinic Hospital Rochester /ID# 278995

    Rochester, Minnesota · Recruiting

  • Novant Health New Hanover Regional Medical Center /ID# 261979

    Wilmington, North Carolina · Recruiting

  • Cleveland Clinic - Cleveland /ID# 277914

    Cleveland, Ohio · Recruiting

  • Penn State Milton S. Hershey Medical Center /ID# 261987

    Hershey, Pennsylvania · Recruiting

  • Prisma Health Greenville Memorial Hospital /ID# 261995

    Greenville, South Carolina · Recruiting

  • Baylor University Medical Center /ID# 261955

    Dallas, Texas · Recruiting

  • Carilion Roanoke Memorial Hospital /ID# 278577

    Roanoke, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.